IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% during the second quarter, Holdings Channel.com reports. The fund owned 299,663 shares of the company’s stock after acquiring an additional 12,317 shares during the period. Parametric Portfolio Associates LLC’s holdings in IDEXX Laboratories were worth $82,506,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Altshuler Shaham Ltd purchased a new position in IDEXX Laboratories in the 2nd quarter valued at about $28,000. Cornerstone Advisors Inc. lifted its holdings in IDEXX Laboratories by 100.0% in the 2nd quarter. Cornerstone Advisors Inc. now owns 140 shares of the company’s stock valued at $39,000 after purchasing an additional 70 shares in the last quarter. Monetary Management Group Inc. purchased a new position in IDEXX Laboratories in the 1st quarter valued at about $45,000. Personal Wealth Partners purchased a new position in IDEXX Laboratories in the 2nd quarter valued at about $52,000. Finally, Next Capital Management LLC lifted its holdings in IDEXX Laboratories by 81.9% in the 2nd quarter. Next Capital Management LLC now owns 191 shares of the company’s stock valued at $53,000 after purchasing an additional 86 shares in the last quarter. 87.04% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Giovani Twigge sold 2,300 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $274.44, for a total value of $631,212.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Jonathan W. Ayers sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.26, for a total transaction of $5,245,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 73,305 shares of company stock worth $19,402,442. Insiders own 2.70% of the company’s stock.

Shares of IDXX stock traded down $4.54 during trading hours on Friday, hitting $266.51. 12,050 shares of the company were exchanged, compared to its average volume of 365,627. The firm has a market cap of $23.04 billion, a PE ratio of 62.47 and a beta of 0.85. IDEXX Laboratories, Inc. has a 1 year low of $176.11 and a 1 year high of $292.17. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 4.49. The firm has a fifty day moving average of $279.08 and a 200 day moving average of $252.99.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.06. The business had revenue of $620.10 million for the quarter, compared to analyst estimates of $627.10 million. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The company’s revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.23 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 4.86 earnings per share for the current year.

A number of research analysts have issued reports on IDXX shares. Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a report on Monday. They issued a “neutral” rating and a $277.00 target price on the stock. Bank of America set a $300.00 target price on shares of IDEXX Laboratories and gave the company a “buy” rating in a report on Friday, June 21st. Canaccord Genuity restated a “buy” rating and issued a $285.00 target price on shares of IDEXX Laboratories in a report on Friday, August 2nd. Credit Suisse Group increased their price objective on shares of IDEXX Laboratories from $282.00 to $293.00 and gave the stock an “outperform” rating in a report on Friday, August 16th. Finally, Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. IDEXX Laboratories presently has an average rating of “Buy” and a consensus target price of $285.29.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: Limitations of the P/E Growth ratio

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit